<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9036">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05706623</url>
  </required_header>
  <id_info>
    <org_study_id>TA799-015</org_study_id>
    <nct_id>NCT05706623</nct_id>
  </id_info>
  <brief_title>A Phase 1, Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function</brief_title>
  <official_title>A Phase 1, Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VectivBio AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VectivBio AG</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess the PK of apraglutide in subjects with hepatic impairment&#xD;
      compared with matched control subjects with normal hepatic function following single SC dose&#xD;
      administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A two stage design, open label, multi-center, non-randomized trial to evaluate the the safety&#xD;
      and tolerability of a single subcutaneous dose of 5 mg apraglutide in subjects with varying&#xD;
      degrees of hepatic function. The hepatic function will estimated with the Child-Pugh&#xD;
      classification.&#xD;
&#xD;
      Part 1: 8 subjects with moderate hepatic impairment (Cohort 1) and 8 subjects with normal&#xD;
      hepatic function (Cohort 2).&#xD;
&#xD;
      Part 2: 8 subjects with mild hepatic impairment (Cohort 3) and 8 subjects with normal hepatic&#xD;
      function (from Cohort 2 where possible and additional subject). Part 2 will be conducted only&#xD;
      if the geometric mean ratio (GMR) of AUCinf or AUClast for the moderate hepatic impairment&#xD;
      group compared to the control group is ≥2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 9, 2023</start_date>
  <completion_date type="Anticipated">July 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 10, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma apraglutide primary PK parameter: AUCinf or AUClast</measure>
    <time_frame>0 to 312 hours</time_frame>
    <description>Area under the curve to infinity (AUCinf) or area under the curve from time zero to the last quantifiable concentration (AUClast) if AUCinf cannot be reliably estimated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma apraglutide primary PK parameter: AUC0-168h</measure>
    <time_frame>0 to 168 hours</time_frame>
    <description>Area under the curve from time zero to 168 hours after apraglutide administration (AUC0-168h)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>0 to 168 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of maximum plasma concentration (tmax)</measure>
    <time_frame>0 to 168 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance after extravascular administration (CL/F)</measure>
    <time_frame>0 to 168 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution after extravascular administration (Vz/F)</measure>
    <time_frame>0 to 168 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination rate constant (λz)</measure>
    <time_frame>0 to 168 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t½)</measure>
    <time_frame>0 to 168 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, nature,and severity of adverse events (AE) with apraglutide</measure>
    <time_frame>Baseline to Day 16</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Moderate hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Child-Pugh B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal hepatic function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Child-Pugh A</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apraglutide</intervention_name>
    <description>Single dose of apraglutide 5mg.</description>
    <arm_group_label>Mild hepatic impairment</arm_group_label>
    <arm_group_label>Moderate hepatic impairment</arm_group_label>
    <arm_group_label>Normal hepatic function</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All Participants:&#xD;
&#xD;
          -  Age between 18 and 75 years inclusive&#xD;
&#xD;
          -  Subjects who are willing and able to comply with the study procedures&#xD;
&#xD;
          -  Subjects able to understand and willing to sign the informed consent&#xD;
&#xD;
          -  Body mass index (BMI) of ≥18 to ≤35 kg/m2; and a total body weight of &gt;50 kg (110 lb).&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) on highly effective method of contraception&#xD;
             during the trial and for 1 month after the end of trial (EOT) visit. Sterilized or&#xD;
             infertile or postmenopausal females.&#xD;
&#xD;
          -  Male subjects with a female partner of childbearing potential: highly effective&#xD;
             methods of contraception and no sperm donation during the trial and for 1 month after&#xD;
             (EOT) visit.&#xD;
&#xD;
        Participants with impaired hepatic function:&#xD;
&#xD;
          -  Confirmed and documented diagnosis of cirrhosis&#xD;
&#xD;
          -  Moderate liver disease (Child-Pugh B): clinically stable for at least 1 month prior to&#xD;
             screening&#xD;
&#xD;
          -  Mild liver disease (Child-Pugh A): clinically stable for at least 1 month prior to&#xD;
             screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of clinically significant GI, bronchopulmonary, neurological, cardiovascular,&#xD;
             endocrine, or allergic disease&#xD;
&#xD;
          -  Known hypersensitivity to the investigational medicinal product (IMP), any of their&#xD;
             excipients or drugs of the same class&#xD;
&#xD;
          -  If capable of reproduction, unwilling to use an effective form of contraception&#xD;
&#xD;
          -  If a female of child-bearing potential, a positive urine/blood pregnancy test&#xD;
&#xD;
          -  Breast-feeding women&#xD;
&#xD;
          -  Positive urine/blood test for alcohol and drugs of abuse at Screening and on Day-1&#xD;
&#xD;
          -  Use of prohibited medications or herbal remedies&#xD;
&#xD;
          -  Known presence or history of intestinal polyps&#xD;
&#xD;
          -  Known presence or history of any type of cancer&#xD;
&#xD;
          -  Pancreatic events such as acute pancreatitis, pancreatic duct stenosis, pancreas&#xD;
             infection, and increased blood amylase and lipase (&gt;2.0-5.0×upper limit of normal&#xD;
             range)&#xD;
&#xD;
          -  Participation in an investigational drug or device study within 30 days prior to&#xD;
             Screening&#xD;
&#xD;
          -  Donation of blood over 500 mL within 2 months prior to Screening&#xD;
&#xD;
          -  Heavy use of tobacco products (i.e., smokes more than 10 cigarettes per day)&#xD;
&#xD;
          -  Concomitant disease or condition that could interfere with, or for which the treatment&#xD;
             of might interfere with, the conduct of the study, or that would, in the opinion of&#xD;
             the Investigator, pose an unacceptable risk to the subject in this trial&#xD;
&#xD;
          -  Any intercurrent clinically significant illness in the previous 28 days before Day 1&#xD;
             of this study&#xD;
&#xD;
          -  Positive blood screen for human immunodeficiency virus (HIV) antigen/antibody combo,&#xD;
             hepatitis A (HAV), hepatitis B surface antigen (HBsAgB), or hepatitis C virus (HCV)&#xD;
&#xD;
          -  Unwillingness or inability to comply with the study protocol for any other reason&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bolognani</last_name>
    <role>Study Director</role>
    <affiliation>VectivBio AG</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lasiene</last_name>
    <phone>+41615513030</phone>
    <email>clinicaltrials@vectivbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>APEX</name>
      <address>
        <city>Münich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Summit Clinical Research</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 20, 2023</study_first_submitted>
  <study_first_submitted_qc>January 20, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2023</study_first_posted>
  <last_update_submitted>February 22, 2023</last_update_submitted>
  <last_update_submitted_qc>February 22, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic Impairment</keyword>
  <keyword>Liver Function</keyword>
  <keyword>Hepatic Function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

